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Ischemia-reperfusion (I/R) damage develops 
when liver blood fl   ow is interrupted, or se-
verely diminished, for a long period of time and 
then restarted. Ischemia may induce cell death 
by itself by causing ATP depletion, but mainly 
primes the cells for the more intense damage 
that occurs when the liver is reperfused (1). 
Upon reentry of oxygen, uncoupled dysfunc-
tional mitochondria produce large amounts of 
oxygen-free radicals, intense oxidative stress, 
and mitochondrial permeability transition lead-
ing to cell death (1). On reperfusion activation 
of Kupff  er cells also occurs, leading to abundant 
production of reactive oxygen species and pro-
infl  ammatory cytokines, further enhancing or-
gan damage (1). I/R injury can cause cell death 
by apoptosis or necrosis (1) depending on the 
intensity of ATP depletion. I/R liver damage is 
of great clinical importance because it can cause 
primary graft nonfunction after liver transplan-
tation and may critically compromise the func-
tion of the remaining liver after major hepatic 
resections (2). The development of new thera-
peutic approaches to control I/R injury may 
benefi  t from better understanding of the defen-
sive mechanisms set into motion in the liver 
when it is subjected to ischemic insults.
In the liver, and in various tissues, it has 
been shown that a short period of ischemia 
protects effi   ciently against subsequent I/R in-
jury (3). This phenomenon, known as ischemic 
preconditioning (IP), indicates that a brief isch-
emic insult triggers a protective biological  reaction 
in the liver which is associated with inhibi-
tion of proapoptotic pathways (3, 4). Although 
  several mechanisms have been invoked, there 
is increasing evidence supporting that a sub-
lethal oxidative stress, as occurs during a short 
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ischemic interval, plays a crucial role in the induction of 
IP (4). In this regard recent reports have demonstrated that 
the protective eff  ect granted by IP on subsequent isch-
emic injury can be mimicked by treatment with H2O2 or an 
H2O2 analogue (5, 6). However, the downstream eff  ectors 
of the protective action of reactive oxygen species are still 
not known.
Cardiotrophin (CT)-1 is member of the IL-6 family of 
cytokines that binds to a specifi  c receptor that contains gp130 
and leukemia inhibitory factor receptor (7). gp130 is com-
mon to the receptor complex of other members of IL-6 su-
perfamily and is required for both ligand binding and signal 
transduction (7). CT-1 is expressed by both parenchymal and 
nonparenchymal liver cells and exerts potent antiapoptotic 
eff  ects on hepatocytes (8). In these cells, as in cardiomyocytes 
and neurons, CT-1 activates cell survival signaling pathways 
including STAT3, extracellular-regulated kinase (Erk)1/2, 
and protein kinase B (Akt) (8–10). In the present work we 
have analyzed the possible role of CT-1 as a natural defense 
of the liver against I/R injury.
RESULTS AND DISCUSSION
Treatment with recombinant CT-1 reduces I/R liver injury
To determine if CT-1 was able to attenuate I/R injury, 400 
μg/kg of body weight of recombinant rat CT-1 (rCT-1) 
was administered to Wistar rats 10 min before clamping 
the artery of the medium and left liver lobes. Samples were 
obtained at 6 h of reperfusion after 1 h of ischemia. We 
found that although untreated rats showed a marked rise of 
serum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) and exhibited large areas of necrosis in the 
liver biopsy, those that were pretreated with CT-1 showed 
little variation of transaminases and no relevant histological 
changes in the liver parenchyma (Fig. 1, A and B). Subse-
quent determination of transaminases levels at 12 h of re-
perfusion showed maintained low values in rats pretreated 
with rCT-1 but high levels in untreated animals (unpub-
lished data).
In another set of experiments rCT-1 at the dose of 
800 μg/kg of body weight was given at the time of reper-
fusion after 1 h of ischemia. In these cases serum transami-
nases at 12 h of reperfusion were higher than in animals that 
received CT-1 before ischemia, but still there was signifi  -
cant (P < 0.05) protection compared with untreated rats 
(ALT: 5,726 ± 2,765 and 1,904 ± 478 in untreated and 
rCT-1–treated animals, respectively). These fi  ndings and our 
previous data showing that CT-1 was able to abrogate con-
canavalin A–induced hepatitis (8) indicate that this cytokine 
is able to exert hepatoprotective activity against diverse forms 
of liver damage.
Figure 1.  CT-1 defends the liver against I/R damage. (A) AST and 
ALT levels in the serum of rats after 1 h ischemia and 6 h reperfusion 
(I/R), sham-operated animals, or rats that were treated with CT-1 (400 
μg/kg of weight, i.v.) 10 min before I/R. Values are means ± SD; 8 rats 
were used per treatment. *, P < 0.01 versus I/R. (B) H&E staining of 
representative liver tissue sections from rats that received either saline 
(I/R) or rCT-1 (rCT-1+I/R) before I/R as described previously. (C) ALT 
levels in the serum of WT and CT-1−/− mice after 75 min of ischemia 
and 3 h of reperfusion (I/R). Where indicated mice were treated with 
CT-1 (400 μg/kg of weight, i.v.) 10 min before I/R (rCT-1+I/R). Values 
are means ± SD; 5 mice were used per treatment. #, P < 0.05 versus 
untreated WT mice; §, P < 0.01 versus untreated CT-1−/− mice; 
*, P < 0.05 versus untreated WT mice. (D) H&E staining of representa-
tive liver tissue sections from WT and CT-1−/− mice that received either 
saline (I/R) or rCT-1 (rCT-1+I/R) before I/R as described previously. 
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CT-1 is an essential endogenous defense of the liver 
against I/R injury
Next, we wished to determine if CT-1 might be involved 
in the natural biological process that defends the liver against 
ischemia. To this aim we subjected CT-1–defi  cient mice to 
75-min ischemia of the left and median lobes followed by 
reperfusion. We observed that the rise of serum transminases 
and the severity of hemorrhagic necrosis in the liver tissue that 
was exposed to ischemia were more intense in CT-1–null 
mice than in WT animals when analyzed at 3 h of reperfu-
sion (Fig. 1, C and D). The higher sensitivity to I/R damage 
exhibited by CT-1–defi  cient mice was not caused by some 
abnormality diff  erent from the lack of this cytokine, because 
these mice were protected against I/R injury by administra-
tion of rCT-1 in the same manner as normal animals (Fig. 1, 
C and D). In rCT-1–treated mice (both WT and CT-1–null 
animals) serum ALT levels at 6 and 24 h after reperfusion 
remained signifi  cantly (P < 0.05) lower than in untreated 
animals (unpublished data), indicating that CT-1 treatment 
eff  ectively prevented tissue injury and did not merely delay 
it. These data reveal an up to now unrecognized role of CT-1 
as a natural defense of the liver against I/R damage.
CT-1 is a key executor of liver protection induced 
by ischemic preconditioning
The role played by CT-1 in liver defense against I/R prompted 
us to investigate if this cytokine could be a mediator of the 
protective biological response induced by IP. We observed 
that when the left and median liver lobes of normal mice were 
subjected to a brief period of ischemia and 15 min of reperfu-
sion (IP) followed by 75 min of ischemia and 3 h of reperfu-
sion (I/R injury), the histological liver lesion, the number of 
apoptotic hepatocyte nuclei (as estimated by the terminal de-
oxynucleotide transferase–mediated dUDP nick-end labeling 
[TUNEL] technique), and the rise of serum transaminases 
were markedly reduced compared with those shown by ani-
mals exposed to I/R insult without previous IP (Fig. 2, A–C). 
It has been reported that I/R damage is associated with phos-
phorylation of c-Jun–NH2-terminal kinase (JNK), an oxida-
tive stress–responsive kinase activated during IR liver injury 
(11, 12), and with activation of the proapoptotic caspase 3, a 
critical executor of I/R liver damage (13, 14). We found that 
although I/R injury caused activation of caspase 3 and phos-
phorylation of JNK and c-Jun in liver tissue, these events did 
not occur when I/R was preceded by IP (Fig. 2 D).
In contrast to WT mice, IP lacked protective eff  ect in 
CT-1–defi   cient mice. In these animals the rise of serum 
transaminases, the intensity of the histological liver   damage, 
the abundance of TUNEL-positive hepatocyte nuclei, and the 
activation of caspase 3, JNK, and c-Jun in hepatic tissue after 
I/R were similar in all mice independently of whether they 
had previous exposure to IP or not (Fig. 2, A–D).
STAT3 promotes antiapoptotic eff  ects in many tissues 
  including the liver (15), and it has been shown that the 
gp130-STAT3 signaling pathway mediates the hepatoprotec-
tion induced by gp130 ligands (16). There is also evidence 
Figure 2.  CT-1 is an indispensable mediator of the hepatoprotec-
tive effect induced by ischemic preconditioning. (A) ALT levels in the 
serum of WT and CT-1−/− mice after 1 h of ischemia and 3 h of reperfu-
sion (I/R), preceded or not by ischemic preconditioning (IP) (10 min of 
ischemia followed by 15 min of reperfusion). Values are means ± SD; 
6 mice were used per treatment. *, P < 0.05 versus WT mice subjected to 
I/R; #, P < 0.05 versus WT mice without IP. (B) H&E staining of represen-
tative liver tissue sections from WT and CT-1−/− mice after I/R preceded 
or not by ischemic preconditioning (IP). (C) TUNEL staining of representa-
tive liver sections from WT and CT-1−/− mice after I/R preceded or not by 
ischemic preconditioning (IP). (D) Representative Western blot analyses of 
active caspase 3 p-17, phosphorylated JNK, and phosphorylated c-Jun in 
liver samples from WT and CT-1−/− mice under basal conditions (C), and 
after I/R or I/R preceded by IP (IP+I/R). Bars, 100 μm.2812  CT-1 PROTECTS FROM ISCHEMIC LIVER INJURY | Iñiguez et al. 
implicating STAT3 activation in the development of heart 
and brain protection associated with ischemic precondition-
ing (17, 18), but the mechanisms by which STAT3 is acti-
vated in response to IP remain ill understood. In the present 
work we found activation of STAT3 in hepatic tissue in 
association with liver protection against I/R injury. Thus, 
marked STAT3 phosphorylation together with nuclear 
translocation of STAT3 in hepatocytes were found in nor-
mal mice exposed to I/R challenge preceded by IP or rCT-1 
administration but not in those subjected to I/R without 
previous treatment (Fig. 3, A and B). In contrast, IP was 
unable to induce STAT3 activation in CT-1–null mice in 
accordance with the absence of protective eff  ect of IP in 
these animals. However, there was prominent phosphory-
lation and nuclear translocation of STAT3 in livers from 
CT-1–null mice after I/R when the animals were pretreated 
with rCT-1 (Fig. 3, A and B), a therapy that aff  orded pro-
tection against I/R injury.
Although it has been reported that rCT-1 may defend 
cardiac cells against hypoxic damage (19) and neurones against 
oxidative injury (20), there was no information as to whether 
endogenous CT-1 participates in the biological protective 
response elicited by IP. Our results in CT-1–defi  cient mice 
reveal that CT-1 is a critical mediator of STAT3 activation 
and nuclear translocation in animals exposed to IP and that 
CT-1 is an essential component of the hepatoprotective reac-
tion set into motion by IP.
Administration of neutralizing antibodies to CT-1 blunt 
the protective effect of IP
Once we found that CT-1 was a critical component of the 
defensive mechanism promoted by IP, we wished to deter-
mine whether the IP could aff  ect the expression of CT-1 in 
liver tissue. We observed that the hepatic levels of CT-1 pro-
tein did not change after 10 min of ischemia and 15 min of 
reperfusion (Fig. 4 A), suggesting that IP has no manifest ef-
fect on CT-1 synthesis. We reasoned that IP might provoke 
the release of preformed cytokine to the extracellular milieu 
to induce local autocrine and paracrine eff  ects. To evaluate 
this possibility we performed an experiment consisting of the 
administration of neutralizing anti–CT-1 antibodies to mice 
subjected to IP followed by I/R. In agreement with our 
  previous observation showing that IP was not eff  ective in 
CT-1−/− mice (Fig. 2, A–D), neutralization of CT-1 in WT 
mice signifi  cantly (P < 0.05) blunted the protective eff  ect of 
IP on I/R liver injury. This was indicated by the rise in   serum 
AST and ALT levels, and by the activation of caspase 3 in the 
liver of mice treated with anti–CT-1 antibody compared 
with controls (IgG) (Fig. 4, B and C). Anti–CT-1 antibody 
administration to sham-operated mice had no eff  ect on   serum 
transaminases levels (unpublished data). These observations 
further confi  rmed the hepatoprotective role of CT-1, and 
also suggested that CT-1 must be released from intracellular 
stores to the extracellular milieu to mediate the hepatopro-
tective eff  ects of IP. We were unable to detect by ELISA cir-
culating CT-1 either in basal condition or after IP (unpublished 
data). It seems possible that CT-1 may act mainly paracrinally 
during IP.
Oxidative stress induces the release of CT-1 
from hepatocytes to extracellular milieu
It has been shown that a sublethal oxidative stress is a key 
event that mediates the cytoprotective eff  ect of IP in the 
liver (5, 6). Sublethal concentrations of oxygen-free radicals, 
likely produced by Kupff  er cells (6), are thought to trigger 
protective mechanisms on subsequent periods of ischemia; 
however, the identity of such mechanisms remains elusive 
(5). Therefore, we analyzed whether isolated hepatocytes 
from normal mice could release CT-1 upon exposure to a 
prooxidant such as the H2O2 analogue tert-butyl-hydroper-
oxide (tBuOOH), previously shown to mimic the eff  ect of 
IP in mice (5). Western blot analysis of the supernatant of 
cultured hepatocytes at 30 and 60 min of incubation showed 
absence of CT-1 in the medium of nonstimulated cells, 
whereas a strong signal was observed at 60 min of incubation 
with tBuOOH (Fig. 4 D). A slight increase in the intracel-
lular levels of CT-1 protein was observed after 60 min of 
treatment with tBuOOH (Fig. 4 D). This could be inter-
preted as a compensatory response to replenish intracellular 
stores of CT-1 after oxidative stress–stimulated release of 
this cytokine. From these observations it is conceivable that 
the oxidative stress generated during IP is responsible for the 
release of CT-1 to extracellular milieu. Our present data 
shed light on the mechanism by which oxidative stress pro-
motes IP-induced hepatoprotection by showing that this 
event leads to CT-1 release, and that this cytokine is essen-
tial for the cytoprotective eff  ect to occur because it is absent 
in CT-1–null mice.
Figure 3.  CT-1–defi  cient mice fail to activate STAT-3 in liver cells 
after ischemic preconditioning. (A) Representative Western blot analyses 
of STAT3 phosphorylation (tyr 705) and STAT3 protein levels in the liver of WT 
and CT-1−/− mice under basal conditions (C), and after I/R or I/R preceded by 
IP (IP+I/R) or by CT-1 treatment (rCT-1+I/R). (B) Immunohistochemical 
  detection of phosphorylated STAT3 in representative liver sections from WT 
and CT-1−/− mice after I/R, I/R preceded by IP, or in mice treated with CT-1 
(400 μg/kg of weight, i.v.) 10 min before I/R (rCT-1+I/R). Bar, 100 μm.JEM VOL. 203, December 25, 2006  2813
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CT-1 but not IL-6 mediates the liver defense against 
brief ischemia
The phenomenon of IP indicates that normal livers tolerate a 
short period of ischemia (and reperfusion) well by setting into 
motion protective mechanisms that adapt the phenotype of 
the tissue not only to resist this brief I/R insult but also to ac-
quire tolerance to subsequent I/R of longer duration. The 
inability of CT-1–null mice to elicit protective IP suggests 
that CT-1 might also be essential to defend the liver against 
ischemia of short duration. Because IL-6 has been suggested 
to play a role in the modulation of I/R liver damage, and 
treatment with recombinant IL-6 substantially protects from 
ischemic liver injury (21), we decided to compare the relative 
role of CT-1 and IL-6 in the defense of the liver against brief 
I/R. To this aim we exposed the left and median lobes of the 
liver of WT mice, CT-1–null mice, and IL-6–null mice to 
10 min of ischemia followed by 15 min of reperfusion, and at 
the end of this time we analyzed serum AST and ALT values 
and the activation of survival factors STAT3 and Akt in he-
patic tissue. We observed that in both WT and IL-6–null 
mice AST and ALT levels showed little change with respect 
to control values. This resistance to short I/R exposure was 
associated with STAT3 and Akt activation in the two groups 
of animals, although with less intensity in IL-6–defi  cient 
mice (Fig. 5, A and B). In sharp contrast, in CT-1–null mice 
AST and ALT were considerably elevated and there was no 
sign of STAT3 activation and only a faint signal of phosphor-
ylated Akt (Fig. 5, A and B). This fi  nding reveals that CT-1, 
rather than IL-6, is a critical factor in the defense of the liver 
against ischemia of short duration.
The role of CT-1 as a natural defense against I/R liver in-
jury and the ability of rCT-1 to protect against this form of he-
patocellular damage point to potential therapeutic   applications 
of rCT-1. New eff  ective therapies are urgently needed for pa-
tients undergoing large hepatic resections because avoidance of 
I/R damage may have an important   impact on postoperative 
morbidity and mortality by improving the function of the re-
maining small liver. The attractiveness of rCT-1 as a potential 
drug in liver surgery is enhanced by the striking increase in the 
number of hepatic surgical   interventions during the last years 
owing to the frequent practice of major hepatic resections for 
primary or metastatic liver cancer and the increasing applica-
tion of living donor liver transplantation.
MATERIAL AND METHODS
Animals. We followed University of Navarra guidelines for the use of labo-
ratory animals. Male Wistar rats (250–275 g) were from Harlan. C57/BL6 
CT-1–null mice (CT-1−/−) (22) and WT mice were a gift from Dr. M. Selzner 
(Zurich University Hospital, Zurich, Switzerland). C57/BL6 IL-6–null mice 
(IL-6−/−) were from The Jackson Laboratory.
Surgical procedure. Rats anesthetized with isofl  urane (Abbott) were sub-
jected to segmental hepatic ischemia followed by reperfusion (23). They 
were killed after 1 h of ischemia and 6 or 12 of reperfusion (I/R), and serum 
and liver biopsies were harvested. Sham animals were manipulated identi-
cally but without vascular clamping.
A similar I/R procedure was performed in CT-1–/– and WT male mice 
8–10 wk old (5). The left and median lobes were occluded for 75 min, and 
Figure 4.  The protective effects of IP are blunted by anti–CT-1–
neutralizing antibodies. Release of CT-1 from isolated hepatocytes upon 
induction of oxidative stress. (A) CT-1 is not up-regulated in IP. Represen-
tative Western blot analysis of CT-1 protein levels in the liver of WT and 
CT-1−/− mice under basal conditions (C) or after ischemic preconditioning 
(IP). Actin levels are shown as loading control. (B) Neutralizing antibody to 
CT-1 impairs the protective effect granted by IP on I/R liver injury. ALT and 
AST levels in the serum of mice that received saline (S), 50 μg of preimmune 
IgG (IgG), or increasing doses of CT-1–neutralizing antibody (anti–CT-1) 
15 min before IP, and subsequently underwent I/R. *, P < 0.05 versus 
mice that received preimmune IgG. (C) Representative Western blot analy-
ses of active caspase 3 p-17 in liver samples from mice treated as de-
scribed in B. Actin levels are shown as loading control. (D) Representative 
Western blot analyses of CT-1 protein levels in the conditioned culture 
medium and cell lysates obtained from control mouse hepatocytes (C) or 
hepatocytes treated with tBuOOH (500 μM) for different periods of time. 
Ponceau S stain of Western blot membranes and actin levels are shown as 
loading controls.2814  CT-1 PROTECTS FROM ISCHEMIC LIVER INJURY | Iñiguez et al. 
after 3 h of reperfusion mice were killed for blood and tissue sampling. 
Where indicated IP consisting of 10 min of ischemia followed by 15 min of 
reperfusion was performed before I/R. Also where indicated, goat preim-
mune IgG (Sigma-Aldrich) or CT-1–neutralizing antibodies (R&D Systems) 
were administered i.v. to WT mice 15 min before IP+I/R. WT, CT-1–/–, 
and IL-6–/– mice were subjected to brief ischemia of 10 min and killed after 
15 min of reperfusion.
Liver samples were snap frozen in liquid nitrogen or formalin fi  xed and 
paraffi   n embedded for histological studies. Serum was used for AST and 
ALT aminotransferases analysis.
Rats were given 400 μg/kg body weight of rCT-1 (8) i.v. 10 min be-
fore ischemia or 800 μg/kg body weight just after declamping. In mice 400 
μg/kg body weight of rCT-1 was injected 10 min before ischemia. These 
doses were selected based on dose–response studies performed in mice and 
were extrapolated to rat experiments. In these experiments, a clear protec-
tive eff  ect was already observed at 200 μg/kg body weight of rCT-1, and 
protection was maximal at 400 μg/kg body weight. The rCT-1 that was 
used for these studies contained 0.14 pg/μg protein of LPS (Limulus amoe-
bocyte lysate assay; Cambrex).
Histological analysis. Hematoxylin and eosin (H&E) staining and TU-
NEL assay (Roche Applied Science) were performed on paraffi   n-embedded 
liver sections as described (8, 24). Immunohistochemistry was performed 
on paraffi     n-embedded liver sections using a polyclonal anti–P-STAT3 
(tyr 705) antibody (Cell Signaling) (25). The EnVision kit (Dako) was used 
for detection.
Western blot. Western blot was performed (24) using antibodies specifi  c 
for caspase 3, P-STAT3 (tyr 705), STAT3, P-Akt, Akt (Cell Signaling), 
P-JNK, P–c-Jun (Santa Cruz Biotechnology, Inc), actin (Sigma-Aldrich), 
and CT-1 (R&D Systems).
In vitro studies. Mouse primary hepatocytes were isolated and cultured as 
described (25). After adhesion, hepatocytes were treated for 30 or 60 min 
with 500 μM of tBuOOH (Sigma-Aldrich). Cells were lysed for Western 
blot analyses as previously described (24). Conditioned medium was har-
vested and concentrated before Western blot analysis. Cell viability was not 
aff  ected by tBuOOH treatment because no diff  erences were observed in 
lactate dehydrogenase activity between the supernatant of control and treated 
hepatocytes, as assessed by the CytoTox-ONE assay from Promega.
Statistical analysis. Statistical methods used were as described previously 
(26). Data are means ± SD; a p value of < 0.05 was considered signifi  cant.
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